CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
Abstract. Chimeric antigen receptor (CAR)-T-cell therapy has achieved significant success in the treatment of hematologic malignancies. However, treatment-related toxicity and side effects remain the major drawbacks. As an important effector cell in innate immunity, natural killer (NK) cells exert s...
Furkejuvvon:
| Váldodahkkit: | , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Wolters Kluwer Health
2019-10-01
|
| Ráidu: | Blood Science |
| Liŋkkat: | http://journals.lww.com/10.1097/BS9.0000000000000028 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|